Lercanidipine Hcl Sandoz (Lercanidipine Hydrochloride)

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

• Essential hypertension: reduces both systolic and diastolic blood pressure in patients with primary high blood pressure.
• Isolated systolic hypertension: helps lower elevated systolic pressure, particularly in older adults.
• Hypertensive patients with cardiovascular risk: contributes to overall risk reduction by improving vascular tone.

• Lercanidipine selectively inhibits calcium influx through L-type calcium channels located on vascular smooth muscle cells. By blocking these channels, it prevents calcium‑mediated contraction, leading to vasodilation of peripheral arteries. The resulting decrease in peripheral vascular resistance lowers systemic blood pressure, providing antihypertensive control without significant effect on heart rate.

Adverse reactions may occur with Lercanidipine therapy. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after dose initiation.
• Peripheral edema: swelling of ankles or lower limbs due to fluid accumulation.
• Flushing: transient warmth and redness of the skin.
• Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Angioedema: rapid swelling of face, lips, tongue, or throat requiring immediate medical attention.
• Myocardial infarction: rare occurrence of heart attack symptoms.
• Significant liver enzyme elevation: abnormal liver function tests indicating possible hepatic injury.

Before initiating therapy, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for existing heart failure or unstable angina.
• Renal function: adjust use in patients with severe renal impairment.
• Hepatic function: monitor liver enzymes in patients with known liver disease.
• Concomitant antihypertensives: avoid excessive blood pressure reduction when combined with other agents.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma concentrations.
• Grapefruit juice: may elevate drug levels and heighten hypotensive effects.
• Simultaneous use with other calcium channel blockers: risk of additive vasodilation and severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood pressure‑lowering effect, necessitating dose adjustments.

• Beta‑blockers: combined therapy may require monitoring for bradycardia or excessive blood pressure reduction.